Trial Profile
Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary) ; Imatinib (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- Acronyms Artesynib
- 12 Oct 2018 New trial record